Pharmaceuticals - Indian - Formulations
Ajanta Pharmaceuticals Ltd. was established in 1973. Headquartered in Mumbai, India, the company has grown into a prominent player in the pharmaceutical industry. It specializes in developing, manufacturing, and marketing pharmaceutical formulations across various therapeutic segments. This includes cardiology, dermatology, ophthalmology, and pain management. The company is recognized for its innovative approach. This has helped it secure leadership positions in multiple molecules and therapeutic areas. Ajanta Pharmaceuticals is not explicitly labelled as the top stock in its sector. However, its significant market presence and growth trajectory reflect its importance in the industry. Read More...
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 4,293.31 | 3,841.28 | 3,456.67 | 2,915.67 | 2,680.06 |
Total Expenses | 3,179.38 | 3,096.03 | 2,547.19 | 2,015.49 | 2,012.17 |
Profit Before Tax | 1,113.93 | 745.25 | 909.48 | 900.18 | 663.97 |
Profit After Tax | 816.17 | 587.98 | 712.68 | 653.87 | 467.70 |
Operating Profit after Depreciation | 1,121.14 | 751.09 | 919.68 | 908.45 | 679.80 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 1,479.19 | 1,496.44 | 1,503.58 | 1,532.21 | 1,462.75 |
Total Non Current Assets | 1,907.47 | 1,845.02 | 1,791.12 | 1,751.13 | 1,676.98 |
Total Current Assets | 2,730.92 | 2,834 | 2,264.46 | 2,027.59 | 1,641.71 |
TOTAL ASSETS | 4,638.39 | 4,679.02 | 4,055.58 | 3,778.72 | 3,318.69 |
Total Shareholder's Fund | 3,567.36 | 3,387.99 | 3,264.34 | 2,995.63 | 2,598.87 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 785.07 | 792.11 | 561.71 | 576.31 | 456.77 |
Net Cash used in Investing Activities | 65.39 | -559.60 | -74.10 | -282.38 | -224.40 |
Net Cash used in Financing Activities | -1,051.06 | -108.20 | -459.71 | -318.29 | -128.63 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 4,087.60 | 3,544.02 | 3,280.37 | 2,822.16 | 2,380.62 |
Total Expenses | 2,990.65 | 2,844.17 | 2,379.83 | 1,920.07 | 1,764.03 |
Profit Before Tax | 1,096.95 | 699.85 | 900.54 | 902.09 | 612.67 |
Profit After Tax | 807.24 | 558.72 | 719.86 | 675.64 | 441.13 |
Operating Profit after Depreciation | 1,103.75 | 705.08 | 909.66 | 908.99 | 625.69 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 1,464.89 | 1,484.01 | 1,483.91 | 1,509.89 | 1,439.93 |
Total Non Current Assets | 1,775.77 | 1,753.60 | 1,723.48 | 1,695.85 | 1,634.07 |
Total Current Assets | 2,441.67 | 2,551.19 | 2,057.01 | 1,836.21 | 1,415.08 |
TOTAL ASSETS | 4,217.44 | 4,304.79 | 3,780.49 | 3,532.06 | 3,049.15 |
Total Shareholder's Fund | 3,413.57 | 3,246.45 | 3,169.18 | 2,884.98 | 2,461.30 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 735.35 | 736.29 | 542.34 | 466.99 | 300.88 |
Net Cash used in Investing Activities | 105.02 | -501.31 | -66.04 | -162.68 | -115.91 |
Net Cash used in Financing Activities | -1,047.70 | -105.12 | -457.30 | -268.90 | -134 |
Particulars (in ₹ Cr.) | 2024-12 | 2024-09 | 2024-06 | 2024-03 | 2023-12 |
---|---|---|---|---|---|
Total Revenue | 1,146.13 | 1,186.64 | 1,144.92 | 1,054.08 | 1,105.15 |
Total Expenses | 825.30 | 875.47 | 814.57 | 775.76 | 791.08 |
Profit Before Tax | 307.39 | 290.24 | 322.12 | 278.04 | 290.91 |
Profit After Tax | 232.88 | 216.48 | 245.77 | 202.72 | 210.03 |
Operating Profit after Depreciation | 351.27 | 330.65 | 356.82 | 313.82 | 327.66 |
Particulars (in ₹ Cr.) | 2024-12 | 2024-09 | 2024-06 | 2024-03 | 2023-12 |
---|---|---|---|---|---|
Total Revenue | 1,101.92 | 1,128.91 | 1,077.27 | 926.07 | 1,085.29 |
Total Expenses | 765.59 | 826 | 761.44 | 698.92 | 758.11 |
Profit Before Tax | 332.15 | 309.20 | 310.56 | 225.94 | 305.14 |
Profit After Tax | 252.45 | 234.98 | 236.03 | 162.69 | 220.15 |
Operating Profit after Depreciation | 369.56 | 343.25 | 344.20 | 260.83 | 340.91 |
₹28/Share
Company | Price | Market Cap (in ₹ Cr) |
---|---|---|
Ajanta Pharma Ltd | ₹2,523.40 | ₹31,520.32 |
Sun Pharmaceuticals Industries Ltd | ₹1,699.75 | ₹4,07,826.96 |
Divis Laboratories Ltd | ₹5,949.15 | ₹1,57,931.24 |
Cipla Ltd | ₹1,452.70 | ₹1,17,322.09 |
Torrent Pharmaceuticals Ltd | ₹3,104.95 | ₹1,05,080.90 |
Mankind Pharma Ltd | ₹2,451.35 | ₹1,01,134.59 |
Ajanta Pharma Ltd is quoting at Rs 2786.7, up 2.5% on the day as on 12:44 IST on the NSE. The stock is up 28.7% in last one year as compared to a 6.9% gain in NIFTY and a 15.64% gain in the Nifty Pharma.
03 Feb 2025, 01:00 pm
On 30 January 2025
17 Jan 2025, 09:11 pm
Ajanta Pharma Ltd is quoting at Rs 2759.3, down 1.59% on the day as on 13:19 IST on the NSE. The stock jumped 56.22% in last one year as compared to a 9.67% rally in NIFTY and a 35.4% spurt in the Nifty Pharma index.
26 Dec 2024, 01:35 pm
Ajanta Pharma Ltd is quoting at Rs 2982.3, up 1.25% on the day as on 12:44 IST on the NSE. The stock is up 52% in last one year as compared to a 19.56% spurt in NIFTY and a 38.42% spurt in the Nifty Pharma.
22 Nov 2024, 01:00 pm
Ajanta Pharma Ltd is quoting at Rs 2929.25, up 1.39% on the day as on 12:49 IST on the NSE. The stock is up 48.57% in last one year as compared to a 20.57% jump in NIFTY and a 38.57% jump in the Nifty Pharma index.
19 Nov 2024, 01:05 pm
View More